» Articles » PMID: 5031656

Pharmacodynamics of Propranolol in Renal Failure

Overview
Journal Br Med J
Specialty General Medicine
Date 1972 May 20
PMID 5031656
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacodynamics of propranolol were studied in patients with renal functional impairment. (14)C-labelled propranolol was given either intravenously or by mouth and the disappearance rates of propranolol, 4-hydroxypropranolol, and total radioactive metabolites measured. The renal clearance of total radioactive compounds is directly related to renal function. The half-life of total radioactivity is greatly lengthened in the presence of severe renal failure while the half-lives of the pharmacologically active propranolol and 4-hydroxymetabolite are slightly reduced. There is a suggestion that the absorption of propranolol is delayed in renal failure. No known pharmacological action or side effects from the other metabolic products of propranolol have been recognized. There is still too little well-documented evidence concerning the beta-blocking activity of the unidentified major metabolites of propranolol to suggest any alteration in the dosage regimen used in renal failure.

Citing Articles

Propranolol disposition in renal failure.

Wood A, Vestal R, Spannuth C, Stone W, Wilkinson G, SHAND D Br J Clin Pharmacol. 1980; 10(6):561-6.

PMID: 7470370 PMC: 1430213. DOI: 10.1111/j.1365-2125.1980.tb00511.x.


Pharmacokinetics of atenolol in relation to renal function.

Kirch W, Kohler H, Mutschler E, Schafer M Eur J Clin Pharmacol. 1981; 19(1):65-71.

PMID: 7461026 DOI: 10.1007/BF00558387.


Pharmacokinetics of acebutolol in patients with all grades of renal failure.

Roux A, Aubert P, GUEDON J, Flouvat B Eur J Clin Pharmacol. 1980; 17(5):339-48.

PMID: 7418713 DOI: 10.1007/BF00558446.


Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.

Flouvat B, Decourt S, Aubert P, Potaux L, Domart M, Goupil A Br J Clin Pharmacol. 1980; 9(4):379-85.

PMID: 7378254 PMC: 1429992. DOI: 10.1111/j.1365-2125.1980.tb01065.x.


The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

Hoffmann K, Regardh C, Aurell M, ERVIK M, Jordo L Clin Pharmacokinet. 1980; 5(2):181-91.

PMID: 7363533 DOI: 10.2165/00003088-198005020-00005.


References
1.
Prichard B, GILLAM P . Treatment of hypertension with propranolol. Br Med J. 1969; 1(5635):7-16. PMC: 1981816. DOI: 10.1136/bmj.1.5635.7. View

2.
FOULKES D . The metabolism of C14-ICI 54,450 (myalex) in various species--an in vivo NIH shift. J Pharmacol Exp Ther. 1970; 172(1):115-21. View

3.
ZACHARIAS F, Cowen K . Controlled trial of propranolol in hypertension. Br Med J. 1970; 1(5694):471-4. PMC: 1699423. DOI: 10.1136/bmj.1.5694.471. View

4.
Hayes A, Cooper R . Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey. J Pharmacol Exp Ther. 1971; 176(2):302-11. View